KCM
EBS icon

Kingdon Capital Management’s Emergent Biosolutions EBS Stock Holding History

Kingdon Capital Management’s Portfolio EBS Stock Details EBS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q4 		– Sell
-103,400
Closed -$3.26M – 134
2016
Q3 		$3.26M Buy
+103,400
New +$3M 0.15% 93

Other funds holding EBS

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
GT
Glenmede Trust Philadelphia, Pennsylvania $20.4B AUM
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
AAM
Aberdeen Asset Management Aberdeen, United Kingdom $30B AUM 22.46% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
SCM
Snyder Capital Management San Francisco, California $5.16B AUM 26.72% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

Kingdon Capital Management's EBS Position: Q1 2016 in Review

Kingdon Capital Management sold out of Emergent Biosolutions (EBS) in Q1 2016, closing a stake of 120,142 shares — an estimated $4.81M sold.

Kingdon Capital Management first reported a position in EBS in Q2 2013 and held it in 11 quarters. The position peaked at $13.6M in Q3 2013. 215 funds tracked by Wall St. Rank hold EBS as of Q1 2016.

  • Kingdon Capital Management reported no remaining Emergent Biosolutions position as of Q1 2016 after selling out during the quarter.
  • Kingdon Capital Management sold 120,142 Emergent Biosolutions shares in Q1 2016, an estimated $4.81M.
  • Kingdon Capital Management first reported a position in Emergent Biosolutions in Q2 2013 and held it in 11 quarters.
  • Kingdon Capital Management's Emergent Biosolutions position peaked at $13.6M in Q3 2013.
  • 215 funds tracked by Wall St. Rank held Emergent Biosolutions as of Q1 2016.

Based on Kingdon Capital Management's 13F filing for Q1 2016, filed 16 May 2016.